Complications of Percutaneous Bone Tumor Cryoablation: A 10-year Experience

被引:71
作者
Auloge, Pierre [1 ]
Cazzato, Roberto L. [1 ]
Rousseau, Chloe [2 ,3 ]
Caudrelier, Jean [1 ]
Koch, Guillaume [1 ]
Rao, Pramod [4 ,5 ,6 ]
Chiang, Jeanie Betsy [7 ]
Garnon, Julien [1 ]
Gangi, Afshin [1 ]
机构
[1] Univ Hosp Strasbourg, Nouvel Hop Civil, Dept Intervent Radiol, 1 Pl Hop,BP 426, F-67091 Strasbourg, France
[2] Univ Hosp Rennes, Clin Invest Ctr, INSERM 1414, Rennes, France
[3] Univ Rennes, Rennes, France
[4] Univ Strasbourg, Div Robot, ICube, Strasbourg, France
[5] Univ Strasbourg, Dept Intervent Radiol, ICube, Strasbourg, France
[6] Nouvel Hop Civil, Strasbourg, France
[7] Queen Elizabeth Hosp, Dept Radiol & Imaging, Hong Kong, Peoples R China
关键词
RENAL-CELL CARCINOMA; OSTEOID OSTEOMA; ABLATION; METASTASES; MANAGEMENT; OUTCOMES; BIOPSY; NEEDLE;
D O I
10.1148/radiol.2019181262
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Percutaneous cryoablation has been shown to be effective in the management of painful bone tumors. However, knowledge of the complication rate and risk factors for complication is currently lacking. Purpose: To report the complication rate and associated risk factors for bone tumor cryoablation. Materials and Methods: This retrospective study reviewed complications in 239 consecutive patients (131 men and 108 women; median age, 64 years; age range, 6-86 years) who underwent cryoablation of 320 primary or metastatic bone tumors between January 2008 and November 2017. Common Terminology Criteria for Adverse Events was used to categorize complications as major (grade 3-4) or minor (grade 1-2). Multivariable analysis was performed for variables with P values less than.20, including age, tumor location, adjacent critical structures, number of cryoprobes, and Eastern Cooperative Oncology Group performance status (ECOG-PS). Results: Among the 320 tumors, the total complication rate was 9.1% (29 of 320; 95% confidence interval [CI]: 6%, 12.2%). The major complication rate was 2.5% (eight of 320; 95% CI: 0.8%, 4.2%), with secondary fracture the most frequent complication (1.2% [four of 320]; mean delay, 71 days); cryoablation site infection, tumor seeding, bleeding, and severe hypotension were each observed in 0.3% (one of 320) of procedures. Minor complications included postprocedural pain (2.2% [seven of 320]), peripheral neuropathy (0.9% [three of 320]), and temporary paresthesia (0.9% [three of 320]). For all complications, associated risk factors included ECOG-PS greater than 2 (odds ratio [OR], 3.1 [95% CI: 3, 7.6]; P =.01), long-bone cryoablation (OR, 17.8 [95% CI: 2.3, 136.3]; P =.01), and use of more than three cryoprobes (OR, 2.5 [95% CI: 1.0, 6.0]; P =.04); for major complications, associated risk factors included age greater than 70 years OR, 7.1 [95% CI: 1.6, 31.7]; P =.01) and use of more than three cryoprobes (OR, 23.6 [95% CI: 2.8, 199.0]; P =.01). Conclusion: Bone tumor cryoablation is safe, with a 2.5% rate of major complications, most commonly secondary fracture (1.2%). Major complications are associated with age greater than 70 years and use of more than three cryoprobes. (c) RSNA, 2019
引用
收藏
页码:520 / 527
页数:8
相关论文
共 50 条
  • [31] Acute Pain Service: A 10-Year Experience
    Deni, Francesco
    Greco, Massimiliano
    Turi, Stefano
    Meani, Renato
    Comotti, Laura
    Perotti, Valeria
    Mello, Alessandra
    Colnaghi, Eleonora
    Pasculli, Nicola
    Nardelli, Pasquale
    Landoni, Giovanni
    Beretta, Luigi
    PAIN PRACTICE, 2019, 19 (06) : 586 - 593
  • [32] Perforated Stercoral Ulcer: A 10-Year Experience
    Gough, Aimee E.
    Donovan, Mark N.
    Grotts, Jonathan
    Greaney, Gregory C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, 64 (04) : 912 - 914
  • [33] Percutaneous cryoablation of symptomatic uterine adenomyomas: Initial experience
    Marcelin, Clement
    Brun, Jean-Luc
    Caprais, Julie
    Molina-Andreo, Isabelle
    Jambon, Eva
    Le Bras, Yann
    Hocke, Claude
    Grenier, Nicolas
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2024, 53 (03)
  • [34] Percutaneous Renal Tumor Cryoablation Effect on Renal Function
    Knudsen, Jens Steensen
    Duus, Louise Aarup
    Junker, Theresa
    Mussmann, Bo
    Graumann, Ole
    JOURNAL OF ENDOUROLOGY, 2023, 37 (10) : 1149 - 1155
  • [35] Laparoscopic vs Percutaneous Cryoablation for the Small Renal Mass: 15-Year Experience at a Single Center
    Zargar, Homayoun
    Samarasekera, Dinesh
    Khalifeh, Ali
    Remer, Erick M.
    O'Malley, Charles
    Akca, Oktay
    Autorino, Riccardo
    Kaouk, Jihad H.
    UROLOGY, 2015, 85 (04) : 850 - 855
  • [36] Pediatric traumatic cataracts: 10-year experience of a tertiary referral center
    Gunaydin, Nesrin Tutas
    Oral, Ayse Yesim Aydin
    BMC OPHTHALMOLOGY, 2022, 22 (01)
  • [37] Image-Guided Percutaneous Biopsy for Pancreatic Lesions: 10-Year Experience in a Tertiary Cancer Center
    Stella, Steffan Frosi
    Van Borsel, Mathias
    Markose, George
    Nair, Sabarinath B.
    CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES, 2019, 70 (02): : 199 - 203
  • [38] Postoperative pulmonary complications in awake video-assisted thoracoscopic surgery: Our 10-year experience
    Turhan, Ozlem
    Sivrikoz, Nukhet
    Duman, Salih
    Kara, Murat
    Sungur, Zerrin
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 32 (01): : 75 - 83
  • [39] Breast Reconstruction and Treatment Algorithm for Patients with Complications after Polyacrylamide Gel Injections: A 10-Year Experience
    Patlazhan, Gennadiy
    Unukovych, Dmytro
    Pshenisnov, Kirill
    AESTHETIC PLASTIC SURGERY, 2013, 37 (02) : 312 - 320
  • [40] CT guided cryoablation for locally recurrent or metastatic bone and soft tissue tumor: initial experience
    Susa, Michiro
    Kikuta, Kazutaka
    Nakayama, Robert
    Nishimoto, Kazumasa
    Horiuchi, Keisuke
    Oguro, Sota
    Inoue, Masanori
    Yashiro, Hideki
    Nakatsuka, Seishi
    Nakamura, Masaya
    Matsumoto, Morio
    Chiba, Kazuhiro
    Morioka, Hideo
    BMC CANCER, 2016, 16